Zions Bancorporation National Association UT Buys 557 Shares of Eli Lilly and Company $LLY

Zions Bancorporation National Association UT increased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 10.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,018 shares of the company’s stock after buying an additional 557 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Eli Lilly and Company were worth $6,467,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter worth approximately $12,976,634,000. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the period. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after buying an additional 1,006,885 shares during the period. Amundi lifted its position in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock worth $3,823,977,000 after buying an additional 964,675 shares during the period. Finally, Jennison Associates LLC lifted its position in shares of Eli Lilly and Company by 22.3% during the 4th quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock worth $5,517,059,000 after buying an additional 937,204 shares during the period. Institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approval for a longer-dated EBGLYSS maintenance regimen boosts Lilly’s dermatology franchise and broadens growth beyond obesity and diabetes, while also making the therapy easier for patients to stay on. FDA Ebglyss Decision Adds New Thread To Eli Lilly Growth Story
• Positive Sentiment: Analysts have nudged up FY2026 EPS estimates, reinforcing confidence that Lilly’s earnings momentum remains strong and above consensus expectations. MarketBeat stock background
• Positive Sentiment: Recent reports highlighted strong clinical and commercial momentum across Lilly’s obesity pipeline, including Foundayo and retatrutide, which supports the company’s leadership in GLP-1 and incretin drugs. Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
• Positive Sentiment: Jefferies raised its price target and reiterated a Buy rating, adding to the bullish analyst tone around Lilly’s pipeline and valuation. Is Eli Lilly and Company (LLY) One of the 10 Best Dividend Stocks to Buy According to D. E. Shaw?
• Neutral Sentiment: Lilly also announced an Alzheimer’s licensing deal with AlzeCure that expands its neuroscience pipeline, but the financial impact is still early-stage and tied to future milestones. Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement
• Negative Sentiment: Reuters reported some U.S. employers may start dropping coverage for GLP-1 weight-loss drugs in 2027 as usage rises, which could eventually pressure demand for Zepbound and other obesity treatments. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Analyst Upgrades and Downgrades

Several equities analysts recently commented on LLY shares. Guggenheim restated a “buy” rating and set a $1,183.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Bank of America raised their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research report on Tuesday, May 26th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $1,227.74.

Eli Lilly and Company Trading Down 0.5%

LLY stock opened at $1,138.78 on Thursday. The business has a fifty day moving average price of $989.96 and a 200 day moving average price of $1,015.14. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,182.73. The stock has a market capitalization of $1.07 trillion, a price-to-earnings ratio of 40.45, a P/E/G ratio of 1.25 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the firm posted $3.34 EPS. The business’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 10th. Investors of record on Friday, May 15th were issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend was Friday, May 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.